Following the keynote by Peter Wennink, the conversation continues with a panel discussion in which we will explore the themes from the keynote in further depth and look at the issues from different perspectives.
We are excited to introduce our panel members:
Ben Feringa, Nobel Laureate in Chemistry (2016) and Professor of Molecular Sciences at the University of Groningen. Recognised worldwide for his groundbreaking work in molecular machines and nanotechnology. Member of several leading international academies.
Stephanie Klein Nagelvoort Schuit, Vice-Chair of the Executive Board (Deputy CEO) of UMCG and Professor of Future Healthcare. With over 20 years of experience, she is a driving force behind digital innovation and networked care. Active in various national advisory roles on healthcare and policy.
Jakob Klompien, Brings over 30 years of experience in leadership roles at Rabobank. Now active as a connector and facilitator in regional economic development. Offers a strong perspective on collaboration between economic, social and regional recovery initiatives.
Together, they will lead an engaging discussion on innovation, collaboration and the future of Life Sciences.
Don’t want to miss it? Register now!
Vandaag is bekend gemaakt dat ZonMw verwacht in september een nieuwe subsidieoproep binnen de PharmaNL Shared Development Infrastructure (SDI)-programmalijn te openen.
What if a surgeon could tell within five minutes whether a tumour has been completely removed? That is exactly what LIFE Cooperative member SPCTR is working on. In the Groninger Ondernemers Courant, the SPCTR team talks about their groundbreaking technology, which will allow surgeons to see within five minutes whether a tumour has been completely removed.
MimeCure heeft een investering van 3 miljoen euro binnengehaald voor de ontwikkeling van een regeneratief geneesmiddel voor de behandeling van chronische longziekten, zoals longfibrose. Dankzij deze financiering kan MimeCure de afronding van de preklinische fase versnellen en beginnen met de voorbereidingen voor klinische proeven, die volgens planning eind 2027 van start zullen gaan. De investeringsronde wordt geleid door Addington Investment Group en ondersteund door mede-investeerder Apsara Investments.
